ACOSOG |
American College of Surgeons Oncology Group |
|
ABC |
advanced breast cancer |
|
ABC5 |
5th ESO-ESMO international consensus guidelines for advanced breast cancer |
第5回ESO-ESMO進行乳癌に対する国際コンセンサスガイドライン |
AI |
aromatase inhibitor |
アロマターゼ阻害薬 |
ALND |
axillary lymph node dissection |
腋窩リンパ節郭清 |
AOR |
annual odds of recurrence |
年間再発率 |
APBI |
accelerated partial breast irradiation |
加速乳房部分照射 |
ART |
assisted reproductive technology |
生殖補助医療 |
ASCO |
American Society of Clinical Oncology |
米国臨床腫瘍学会 |
ASTRO |
American Society for Radiation Oncology |
米国放射線腫瘍学会 |
BIA-ALCL |
breast implant-associated anaplastic large cell lymphoma |
ブレスト・インプラント関連未分化大細胞型リンパ腫 |
BMA |
bone modifying agents |
骨修飾薬 |
BMD |
bone mineral density |
骨密度 |
BOOP |
bronchiolitis obliterans organizing pneumonia |
|
CALGB |
Cancer and Leukemia Group B |
|
CAM |
complementary and alternative medicine |
補完・代替療法 |
CBR |
clinical benefit rate |
リニカルベネフィット率 |
CF |
conventional fractionation |
通常分割 |
CGA |
comprehensive geriatric assesment |
高齢者機能的総合評価 |
CI |
confidence interval |
信頼区間 |
CR |
complete response |
完全奏効 |
CTV |
clinical target volume |
臨床標的体積 |
DBCG |
Danish Breast Cancer Cooperative Group |
|
DCIS |
ductal carcinoma in situ |
非浸潤性乳管癌 |
DDFS |
distant disease-free survival |
|
DFI |
disease-free interval |
|
DFS |
disease-free survival |
無病生存期間,無病生存率 |
DIEP flap |
deep inferior epigastric perforator flap |
深下腹壁動脈穿通枝皮弁 |
DRFS |
distant relapse-free survival |
|
EBC |
early breast cancer |
早期乳癌 |
EBCTCG |
Early Breast Cancer Trialists’ Collaborative Group |
|
ECOG |
Eastern Cooperative Oncology Group |
|
EFS |
event-free survival |
無イベント生存率 |
EIC |
extensive intraductal component |
広範な乳管内進展 |
EORTC |
European Organisation for Research and Treatment of Cancer |
|
EORTC QLQ |
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire |
|
ER |
estrogen receptor |
エストロゲン受容体 |
ERE |
estrogen responsive element |
エストロゲン応答配列 |
ESMO |
European Society for Medical Oncology |
欧州臨床腫瘍学会 |
FACT |
Functional Assessment of Cancer Therapy |
|
FDA |
Food and Drug Administration |
米国食品医薬品局 |
FN |
febrile neutropenia |
発熱性好中球減少症 |
FSH |
follicle stimulating hormone |
卵胞(濾胞)刺激ホルモン |
gBRCA |
germline BRCA |
生殖細胞系列BRCA |
G-CSF |
granulocyte-colony stimulating factor |
顆粒球コロニー刺激因子 |
GPA |
graded prognostic assessment |
|
GTV |
gross tumor volume |
肉眼的腫瘍体積 |
HBV |
hepatitis B virus |
B型肝炎ウイルス |
HER2 |
human epidermal growth factor receptor type 2 |
ヒト上皮増殖因子受容体2型 |
HF |
hypofractionation |
寡分割 |
HR |
hazard ratio |
ハザード比 |
HR |
hormone receptor |
ホルモン受容体 |
HRD |
homologous recombination deficiency |
相同組み換え修復不全 |
HRT |
hormone replacement therapy |
ホルモン補充療法 |
IBCSG |
International Breast Cancer Study Group |
|
IBTR |
ipsilateral breast tumor recurrence |
温存乳房内再発 |
IDFS |
invasive disease-free survival |
浸潤癌の無病生存期間 |
IHC |
immunohistochemical staining |
免疫組織化学的方法 |
IMRT |
intensity modulated radiation therapy |
強度変調放射線治療 |
ITT |
intention to treat |
|
JCOG |
Japan Clinical Oncology Group |
日本臨床腫瘍研究グループ |
LABC |
locally advanced breast cancer |
局所進行乳癌 |
LCIS |
lobular carcinoma in situ |
非浸潤性小葉癌 |
LH |
luteinizing hormone |
黄体形成ホルモン |
LH-RH |
luteinizing hormone-releasing hormone |
黄体形成ホルモン放出ホルモン |
LVEF |
left ventricular ejection fraction |
左室駆出率 |
MBC |
metastatic breast cancer |
転移・再発乳癌 |
MMR |
mismatch repair |
ミスマッチ修復機能 |
MSI |
microsatellite instability |
マイクロサテライト不安定性 |
NAC |
neoadjuvant chemotherapy |
術前化学療法 |
NCCN |
National Comprehensive Cancer Network |
全米総合がん情報ネットワーク |
NCI |
National Cancer Institute |
米国国立癌研究所 |
NGS |
next generation sequencing |
次世代シークエンス |
NSABP |
National Surgical Adjuvant Breast and Bowel Project |
|
NSAI |
non-steroidal aromatase inhibitor |
非ステロイド性アロマターゼ阻害薬 |
NSAIDs |
non-steroidal anti-inflammatory drugs |
非ステロイド消炎鎮痛薬 |
NSM |
nipple-sparing mastectomy |
乳頭温存乳房全切除術 |
ONJ |
osteonecrosis of the jaw |
顎骨壊死 |
OPBCS |
oncoplastic breast-conserving surgery |
乳房温存オンコプラスティックサージャリー |
OPBS |
oncoplastic breast surgery |
乳房オンコプラスティックサージャリー |
OR |
odds ratio |
オッズ比 |
ORR |
overall response rate |
全奏効割合,全奏効率 |
OS |
overall survival |
全生存期間,全生存率 |
PARP |
poly(ADP-ribose)polymerase |
ポリADPリボースポリメラーゼ |
pCR |
pathological complete response |
病理学的完全奏効 |
PD |
progressive disease |
進行 |
PD-1 |
programmed cell death-1 |
|
PD-L1 |
programmed cell death 1 ligand 1 |
|
PFS |
progression free survival |
無増悪生存期間,無増悪生存率 |
PgR |
progesterone receptor |
プロゲステロン受容体 |
PMRT |
postmastectomy radiation therapy |
乳房全切除術後放射線療法 |
PS |
performance status |
パフォーマンスステータス |
PTV |
planning target volume |
計画標的体積 |
QALYs |
quality-adjusted life-years |
|
QOL |
quality of life |
生活の質 |
RANKL |
receptor activator of nuclear factor κ-B ligand |
|
RCT |
randomized controlled trial |
ランダム化比較試験 |
RDI |
relative dose intensity |
|
RFA |
radiofrequency ablation |
ラジオ波熱凝固療法 |
RFS |
relapse-free survival,recurrence-free survival |
無再発生存期間,無再発生存率 |
RI |
radioisotope |
ラジオアイソトープ |
RR |
risk ratio |
リスク比 |
RS |
recurrence score |
|
RTOG |
Radiation Therapy Oncology Group |
米国腫瘍放射線治療グループ |
RT-PCR |
reverse transcription polymerase chain reaction |
|
SABCS |
San Antonio Breast Cancer Symposium |
|
SE |
standard error |
標準誤差 |
SEER |
Surveillance, Epidemiology, and End Results |
|
SERD |
selective estrogen receptor degrader |
選択的エストロゲン受容体分解薬 |
SERM |
selective estrogen receptor modulator |
選択的エストロゲン受容体モジュレーター |
SLE |
systemic lupus erythematosus |
全身性エリテマトーデス |
SLN |
sentinel lymph node |
センチネルリンパ節 |
SLNB |
sentinel lymph node biopsy |
センチネルリンパ節生検 |
SRE |
skeletal-related event |
骨関連事象 |
SRS |
stereotactic radiosurgery |
定位手術的照射 |
SRT |
stereotactic radiotherapy |
定位[的]放射線治療 |
SSM |
skin-sparing mastectomy |
皮膚温存乳房全切除術 |
SSO |
Society of Surgical Oncology |
|
SSRI |
selective serotonin reuptake inhibitor |
選択的セロトニン再取込み阻害薬 |
STI |
stereotactic irradiation |
定位放射線照射 |
SWOG |
Southwest Oncology Group |
|
TE |
tissue expander |
組織拡張器 |
TMB-H |
tumor mutational burden-high |
腫瘍遺伝子変異量高スコア |
TNBC |
triple negative breast cancer |
トリプルネガティブ乳癌 |
TPC |
treatment of physician’s choice |
|
TRK |
tropomyosin receptor kinase |
受容体チロシンキナーゼ |
TTNT |
time to next treatment |
次治療までの期間 |
TTP |
time to progression |
無増悪期間,病勢進行までの期間 |
VEGF |
vascular endothelial growth factor |
血管内皮増殖因子 |
WHO |
World Health Organization |
世界保健機関 |
YAM |
young adult mean |
若年成人平均値 |